All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.

FCR Retains Curative Potential in Young Patients With Favorable CLL Biology

September 20th 2023

John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

Montefiore Einstein Comprehensive Cancer Center Awarded Comprehensive Designation from the National Cancer Institute

September 20th 2023

The newly renamed Montefiore Einstein Comprehensive Cancer Center has been awarded comprehensive designation by the National Cancer Institute of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S.

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of pembrolizumab in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy, for the treatment of newly diagnosed patients with high-risk, locally advanced cervical cancer.

Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice

September 20th 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL

September 20th 2023

Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.

FDA Approval Sought for Frontline Tislelizumab in Locally Advanced or Metastatic ESCC

September 19th 2023

The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.

Tislelizumab Approved in Europe for Advanced ESCC After Platinum-Based Chemotherapy

September 19th 2023

The European Commission has approved tislelizumab monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

September 19th 2023

The addition of toripalimab to standard-of-care sorafenib in the frontline setting demonstrated preliminary efficacy and tolerability in patients with unresectable hepatocellular carcinoma.

Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML

September 19th 2023

The European Commission has approved oral decitabine and cedazuridine for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for standard induction chemotherapy.

AHN West Penn Doctors First in Region to Use New Minimally Invasive Technology to Combat Cancer and Target Hard-to-Reach Tumors

September 19th 2023

Interventional Radiologists at Allegheny Health Network's West Penn Hospital are the first in the region, and among the first in the country, to use a cutting-edge new technology called the Aliya Pulsed Electrical Field system, to target and eradicate cancer cells while preserving healthy adjacent tissues.

FDA Grants Priority Review to Belzutifan in Previously Treated Advanced RCC

September 19th 2023

The FDA has granted priority review to the supplemental new drug application seeking the approval of belzutifan for the treatment of previously treated patients with advanced renal cell carcinoma following immune checkpoint and anti-angiogenic therapies.

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

September 19th 2023

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 19th 2023

The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.

FDA Grants Fast Track Designation to KT-333 in R/R CTCL and PTCL

September 18th 2023

The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma and relapsed/refractory peripheral T-cell lymphoma.

Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for CD30+ Stage III Hodgkin Lymphoma

September 18th 2023

The European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.